[In vivo assessment on the therapeutic effects of etoposide, vincristine and mitomycin C against human neuroblastoma].
Anti-tumor effects of etoposide (VP-16), vincristine and mitomycin C were evaluated with four human neuroblastoma xenograft, according to Battelle Columbus Laboratories protocol. Etoposide is one of the agents which has been reported to be effective against advanced neuroblastoma clinically, if combined with other agents. While vincristine was effective against 1 out 4 neuroblastoma xenografts, TS-N-2, with 58.1% maximum inhibition rate, etoposide was assessed ineffective as a single agent in all of the 3 xenografts used. Since etoposide had no effect on the weight gain in nude mice in this xenograft experiment, the dose of etoposide was increased two-fold against 2 xenografts, but found ineffective also in the increased dose. Mitomycin C, which has not been used in childhood malignant tumors, was effective against 2 out of 4 xenografts, TNB-9 and SK-N-AS, with 72.0% and 78.4% maximum inhibition rates, respectively.
Kaneko
M
M
Dept. of Pediatric Surgery, University of Tsukuba.
Kaneko
S
S
Ohkawa
H
H
D000818:Animals; D002675:Child, Preschool; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D009447:Neuroblastoma / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use*
D008937:Mitomycins; D016685:Mitomycin; D014750:Vincristine; D005047:Etoposide